STOCK TITAN

vvy - VVY STOCK NEWS

Welcome to our dedicated page for vvy news (Ticker: vvy), a resource for investors and traders seeking the latest updates and insights on vvy stock.

Vivoryon Therapeutics N.V. (symbol: VVY) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutic solutions for age-related diseases. The company focuses primarily on combating neurodegenerative conditions such as Alzheimer's disease. The core business of Vivoryon involves the research and development of drug candidates that target specific enzymes implicated in the pathogenesis of these diseases.

One of the company's flagship projects is the development of varoglutamstat (PQ912), a first-in-class therapy aimed at inhibiting the enzyme glutaminyl cyclase (QC). This enzyme is known to play a significant role in the formation of toxic proteins associated with Alzheimer's disease. Vivoryon's approach is designed to slow down or halt disease progression by reducing the build-up of these harmful proteins.

Recent achievements include the successful completion of Phase IIb clinical trials for varoglutamstat, which demonstrated promising efficacy and safety profiles. The company is now gearing up for Phase III trials and has received positive feedback from regulatory authorities.

In addition to varoglutamstat, Vivoryon is exploring other therapeutic candidates and biomarkers that could potentially address various aspects of neurodegenerative and age-related disorders. The company's robust pipeline showcases its commitment to expanding its portfolio through both in-house research and strategic partnerships.

Financially, Vivoryon maintains a strong position with a diversified funding strategy that includes grants, partnerships, and equity financing. The company's recent financial results highlighted steady progress in R&D expenditures, reflecting its focused investment in advancing its clinical programs.

Vivoryon collaborates with leading academic institutions and industry partners to leverage cutting-edge research and technology. These partnerships are crucial for accelerating the development of its therapeutic candidates and ensuring access to the latest scientific advancements.

Overall, Vivoryon Therapeutics N.V. is at the forefront of developing new treatments for age-related diseases, with a particular focus on neurodegeneration. Its innovative approach, strong financial health, and strategic partnerships position the company as a significant player in the biopharmaceutical industry.

Rhea-AI Summary

Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) will host an R&D update call on July 18, 2024, at 3:00 pm CEST / 9:00 am EDT, focusing on advancements in kidney disease treatment. The conference will detail further analyses and data on varoglutamstat's beneficial effects on kidney function, along with updates on its clinical development plan. Participants can join via phone or webcast, with a live audio stream available on Vivoryon's website. The event will include a Q&A session for investors and analysts. Pre-registration is required for phone access, and a replay will be available post-presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Vivoryon Therapeutics N.V., a clinical-stage company focused on small molecule medicines, held its 2024 Annual General Meeting (AGM) on June 21 in Halle (Saale) / Munich, Germany. Shareholders approved all proposed items on the agenda. The event, held at 1:00 p.m. (CEST), included a presentation by the management team. Key details and related documents regarding the AGM are accessible on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Vivoryon Therapeutics N.V. reported financial results for Q1 2024, highlighting a strategic shift towards kidney disease following disappointing AD study results. The company observed substantial improvements in kidney function with varoglutamstat. Revenue remained zero, but R&D and administrative expenses rose, leading to a net loss of EUR 9.3 million. Cash reserves stood at EUR 22.0 million, expected to fund operations into Q2 2025. Vivoryon will focus on inflammatory and fibrotic disorders and plans to discontinue the VIVA-MIND study. The 2024 Annual General Meeting is set for June 21 in Amsterdam.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Vivoryon Therapeutics N.V. (VVY) has announced it will report its Q1 2024 financial results and provide an operational update on May 23, 2024. The clinical-stage company, known for developing small molecule medicines targeting altered proteins, will host a public conference call and webcast at 3:00 pm CEST / 9:00 am EDT on the same day.

The webcast will be available on Vivoryon's website, and participants can register for the call in advance to receive dial-in details. Interested parties are encouraged to join the call 15 minutes early to avoid delays.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary

Vivoryon Therapeutics N.V. will hold its 2024 Annual General Meeting on June 21, 2024, focusing on the discovery and development of small molecule medicines to modulate pathologically altered proteins. The meeting will take place in Amsterdam with relevant documents accessible on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Vivoryon Therapeutics N.V. reported its full-year 2023 financial results, highlighting the ongoing analysis of the VIVIAD Phase 2b study and the disappointing outcome regarding varoglutamstat's effect on cognition in early Alzheimer's disease. The company observed a statistically significant improvement in kidney function with varoglutamstat, leading to a shift in strategic focus towards inflammatory and fibrotic disorders. The VIVA-MIND Phase 2 study will be discontinued early to facilitate accelerated data analysis. The company aims to reduce cash utilization and prioritize resources for exploring varoglutamstat in kidney disease, analyzing VIVIAD and VIVA-MIND data, advancing select pipeline programs, and continuing business development. Financially, the company expects its cash runway to extend into Q2 2025 without additional financing, contingent on current plans and the discontinuation of VIVA-MIND.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Vivoryon Therapeutics N.V. will report its full-year 2023 financial results and operational progress on April 24, 2024. The company, focused on developing small molecule medicines to modulate pathologically altered proteins, will host a conference call and webcast open to the public.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary
Vivoryon Therapeutics N.V. announces changes to its Board of Directors with the resignation of Professor Morten Asser Karsdal and Kugan Sathiyanandarajah. The company expresses gratitude for their contributions while focusing on its commitment to developing small molecule medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Vivoryon Therapeutics N.V. announced topline results from its Phase 2b European VIVIAD study of varoglutamstat in early Alzheimer’s disease. The study did not meet its primary and key secondary endpoints, showing no significant difference in cognition improvement. Varoglutamstat was well tolerated with no symptomatic ARIAs. The company is analyzing additional endpoints for insights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) announced that its management team will host investor meetings in January 2024 to discuss its lead program varoglutamstat, a small-molecule medicine in development for Alzheimer's disease. The company remains on track to share VIVIAD Phase 2b final topline data by the end of the first quarter of 2024, with the full dataset to follow at a subsequent medical meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences

FAQ

What is Vivoryon Therapeutics N.V.?

Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical company focused on developing therapies for age-related diseases, particularly neurodegenerative conditions like Alzheimer's disease.

What is the main focus of Vivoryon's research?

Vivoryon focuses primarily on developing therapeutic solutions targeting key enzymes implicated in the pathogenesis of neurodegenerative diseases.

What is varoglutamstat (PQ912)?

Varoglutamstat (PQ912) is Vivoryon's leading drug candidate designed to inhibit the enzyme glutaminyl cyclase (QC), which is involved in the formation of toxic proteins in Alzheimer's disease.

What recent achievements has Vivoryon made?

Vivoryon recently completed Phase IIb clinical trials for varoglutamstat, demonstrating promising efficacy and safety profiles, and is preparing for Phase III trials.

How is Vivoryon funded?

Vivoryon maintains a strong financial position through grants, partnerships, and equity financing, reflecting its commitment to advancing its clinical programs.

Who are Vivoryon's partners?

Vivoryon collaborates with leading academic institutions and industry partners to leverage cutting-edge research and technology.

What other therapeutic candidates is Vivoryon developing?

Besides varoglutamstat, Vivoryon is exploring other therapeutic candidates and biomarkers to address various aspects of neurodegenerative and age-related disorders.

How does Vivoryon contribute to Alzheimer's research?

Vivoryon is at the forefront of Alzheimer's research, focusing on innovative therapies that slow or halt disease progression by targeting specific disease-related enzymes.

What are the future plans for Vivoryon?

Vivoryon's future plans include advancing varoglutamstat to Phase III clinical trials, expanding its therapeutic pipeline, and strengthening strategic partnerships.

How can I get more information about Vivoryon's latest news?

For more information, you can contact Vivoryon's investor and media relations representatives or visit their official website for updates.

vvy

Nasdaq:VVY

VVY Rankings

VVY Stock Data